Literature DB >> 1695784

Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia.

M Caine1.   

Abstract

There seems little doubt that alpha-adrenergic blockers can afford a measure of relief to many sufferers from BPH. The exact role this treatment has to play in the overall management of these patients has yet to be clearly defined. A continuing search is being made for more effective drugs, with the hope of finding one that will be more specific in its action on the prostate and produce fewer generalized effects. Whether this will prove possible may depend on whether any further subgroup of alpha receptors more specific to the prostate can be found or whether some method of targeting the drugs to the required region can be devised. If a drug treatment that reduces the size of the prostate can be found, perhaps a combination of the two forms of medical treatment will have a place. At present, it seems reasonable to conclude that there is good justification for using the alpha-blocking drugs available when employed in the manner and for the indications outlined herein.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1695784

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  6 in total

1.  Effects of castration on contraction and alpha(1)-adrenoceptor expression in rat prostate.

Authors:  Y Homma; K Hamada; Y Nakayama; G Tsujimoto; K Kawabe
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 2.  Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs.

Authors:  N Kyprianou; S C Jacobs
Journal:  Curr Urol Rep       Date:  2000-08       Impact factor: 3.092

3.  Variable selection and specification of robust QSAR models from multicollinear data: arylpiperazinyl derivatives with affinity and selectivity for alpha2-adrenoceptors.

Authors:  D W Salt; L Maccari; M Botta; M G Ford
Journal:  J Comput Aided Mol Des       Date:  2004 Jul-Sep       Impact factor: 3.686

4.  Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonists.

Authors:  Frances M Martin; Andrew M Harris; Randall G Rowland; William Conner; Matthew Lane; Erik Durbin; Andre T Baron; Natasha Kyprianou
Journal:  Gene Ther Mol Biol       Date:  2008

5.  Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.

Authors:  Andrew M Harris; Bradley W Warner; John M Wilson; Aaron Becker; Randall G Rowland; William Conner; Matthew Lane; Kimberly Kimbler; Eric B Durbin; Andre T Baron; Natasha Kyprianou
Journal:  J Urol       Date:  2007-09-17       Impact factor: 7.450

6.  Alpha1-adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells.

Authors:  Stephanie Thebault; Morad Roudbaraki; Vadim Sydorenko; Yaroslav Shuba; Loic Lemonnier; Christian Slomianny; Etienne Dewailly; Jean-Louis Bonnal; Brigitte Mauroy; Roman Skryma; Natalia Prevarskaya
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.